Author:
Kamdem Leonel,Asmar Antoine El,Demetter Pieter,Zana Ismael Coulibaly,Khaled Charif,Sclafani Francesco,Donckier Vincent,Vermeulen Peter,Liberale Gabriel
Abstract
Abstract
Background
Two distinct histological growth patterns (HGPs) were described in patients with peritoneal metastasis of colorectal cancer origin (PMCRC) with limited Peritoneal Cancer Index (PCI) ≤ 6 who did not receive neoadjuvant chemotherapy (NAC) and were treated with cytoreductive surgery (CRS) ± hyperthermic intraperitoneal chemotherapy (HIPEC): pushing HGP (P-HGP) and infiltrating HGP (I-HGP). Patients with dominant P-HGP (> 50%) had significantly better disease-free survival (DFS) and overall survival (OS).
Objective
We aimed to determine whether these previous observations regarding the prognostic value of HGP in patients with PMCRC with low PCI (≤ 6) are also valid in all operable patients, regardless of whether they received NAC or not and regardless of PCI score.
Methods
This was a retrospective study including 76 patients who underwent complete CRS ± HIPEC for PMCRC between July 2012 and March 2019. In each patient, up to five of the largest excised peritoneal nodules were analyzed for their tumor-to-peritoneum interface. Correlations between NAC, HGP, and prognosis were further explored.
Results
Thirty-seven patients (49%) had dominant P-HGP and 39 (51%) had dominant I-HGP. On univariate analysis, patients with P-HGP ≤ 50% had significantly lower OS than those with dominant P-HGP > 50% (39 versus 60 months; p = 0.014) confirmed on multivariate analysis (hazard ratio 2.4, 95% confidence interval 1.3–4.5; p = 0.006). There were no significant associations between NAC and type of HGP.
Conclusions
This study confirms the prognostic value and reproducibility of the two previously reported HGPs in PMCRC. Dominant P-HGP is associated with better DFS and OS in patients undergoing curative-intent CRS ± HIPEC compared with I-HGP, independently of the extent of peritoneal disease burden.
Publisher
Springer Science and Business Media LLC
Reference21 articles.
1. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.
2. Kemeny N. Presurgical chemotherapy in patients being considered for liver resection; presurgical chemotherapy in patients being considered for liver resection. Oncologist. 2007;12:825–39.
3. Manfredi S, Lepage C, Hatem C, et al. Epidemiology and management of liver metastases from colorectal cancer. Ann Surg. 2006;244:254–9.
4. Barat M, Soyer P, Eveno C, et al. The presence of cardiophrenic angle lymph nodes is not an indicator of peritoneal carcinomatosis from colorectal cancer on MDCT: results of a case-control study. Eur J Surg Oncol. 2016;42:266–72.
5. Capussotti L, Ferrero A, Muratore A, et al. (2011) Surgical treatment of colorectal liver metastases. [Google books] 2011. Available at: https://books.google.be/books?hl=en&lr=&id=W1C4oTEnKDAC&oi=fnd&pg=PR4&dq=Muratore+A,+Ribero+D,+Viganos+L+(2011)+Epidemiology+and+natural+history%3B+surgical+treatment+of+colorectal+liver+metastases.+Springer,+Milan,+pp+1-6&ots=LeW9moGYic&sig=PZcObJ8X4-1B7_Gok2C24TpLDt8&redir_esc=y#v=onepage&q&f=false. Accessed 29 Jan 2021.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献